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92 Poster Session-IBronchoscopic BAL (B-BAL) is performed by physicians, using
video-bronchoscope. Non-bronchoscopic BAL (NB-BAL) is per-
formed by respiratory therapists (RT), without direct visualization
of the lower airways. Generally, B-BAL is considered more effective
thanNB-BALdue to concern thatNB-BALperformed byRT can be
associated with higher incidence of complications, especially bleed-
ing. We compared the two methods for obtaining BAL and studied
themicrobiological yield, safety and cost-effectiveness of B-BAL and
NB-BAL in critically ill cancer patients.
Method: Following IRB approval, medical records of all intu-
bated and mechanically ventilated adult ICU patients with pulmo-
nary infiltrates, who underwent either B-BAL or NB-BAL between
8/1/2006 and 10/31/2006, were retrospectively studied. B-BAL
was performed by intensivist or pulmonologist and NB-BAL was
performed using 16Fr Kimberly Clark’s protected BAL catheter,
by experienced and skilled RT according to specific department pol-
icy. The BAL samples were taken from the lower lobe bronchial seg-
ments.Table 1. A comparison of B-BAL and NB-BAL in patients with
hematological malignancies.
Patient Charecteristics n B-BAL NB-BAL44 22 22
Age yrs
Median 52 49 55
Range 20-79 20-79 28-72
M/F 29/15 15/7 14/8Diagnosis
Leukemia 16 10 6
Lymphoma 13 5 8
SCT recipients 13 7 6
Myeloma 1 0 1
Hypereosinophilic syndrome 1 0 1WBC count K/UL
Median 3.3 0.3 5.0
Range 0.1-102 0.1-18 0.1-102Platelet count K/UL
Median 42 29 59
Range 5-321 5-247 23-321
Complications 0 0 0
Microbiological yield 20/44 (46%) 11/22 (50%) 9/22 (41%)Cost per procedure $ 2427 125
SCT recipients
Platelet count K/UL
Median 51 27 52
Range 19-247 19-247 24-98WBC count K/UL
Median 5.2 6.6 3.25Range 0.1-21.2 3.3-9.0 0.1-21.2
Microbiological yield 7/13 (54%) 4/7 (57%) 3/6 (50%)Results:During the study period, 44 critically ill patients with he-
matological malignancies including 13 SCT recipients underwent
BAL. Four patients had received SCT within the prior 4 weeks of
BAL. An equal number of NB-BAL and B-BAL was performed. Pa-
tient characteristics,WBC counts, platelet counts, procedure related
complications, microbiological yield and cost per procedure associ-
ated with B-BAL and NB-BAL are shown in table 1. The most fre-
quently identified organisms were Pseudomonas aeruginosa,
Coagulase negative staphylococcus, Stenotrophomonas maltophilia,
and Candida spp.
Conclusion: Both B-BAL and NB-BAL can be safely performed
in patients with hematological malignancies including SCT recipi-
ents. Microbiological yield is similar between physician performed
B-BAL and RTperformedNB-BAL in critically ill patients with pul-
monary infiltrates. However, the cost of B-BAL is 20 times higher
thanNB-BAL for similar yield, due to physician resource utilization.
Hence, NB-BAL should be considered as a safe alternative whenever
feasible.253
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Background: Disseminated infection by Trichosporon species
(DT) is an uncommon but frequently fatal mycosis in neutropenic
patients, including recipients of hematopoietic stem cell transplanta-
tion (HSCT). However, little is known about the clinical character-
istics and treatment outcome of DT due to its rarity.
Methods: A questionnaire was sent to 468 hospitals in Japan to
survey DT, which was defined as infectious symptoms associated
with positive blood culture for Trichosporon species. In selected pa-
tients, genetic subtypes and antifungal susceptibility of the isolates
were analyzed.
Results: Between 2000 and 2007, 67 patients (median age, 57
years: range, 16–78) with a variety of hematological diseases devel-
oped DT. The diagnosis included acute myeloid leukemia (n 5
39), acute lymphoblastic leukemia (8), chronic myeloid leukemia
(6), and lymphoma (6), and 28 patients (42%) were recipients of
HSCT. At the onset of DT, 55 patients (82%) had an absolute neu-
trophil count below 500 /mm3, and 58 patients (87%) had been re-
ceiving antifungal agents, including micafungin (MCFG) in 39
patients. In 35 patients (52%), Trichosporon species were detected
in various organs including lung (n 5 18), kidney (12), heart (6),
and skin (6). A beta-D-glucan test was positive in 43 of the 62 eval-
uated patients (median, 96 pg/ml; range, 22–3961). Whereas 2 iso-
lates of T. asahi appeared to be resistant to all antifungal agents
including azoles, 22 isolates showed good susceptibility to voricona-
zole, but not to MCFG. Although 56 of the 67 patients (84%) re-
ceived various antifungal agents for DT, the mortality rate within
30 days was 67% (median survival time, 13 days). Overall survival
was significantly better in patients who received azoles rather than
amphotericin products without azole (p5 0.0002). In a multivariate
analysis, treatment without azoles for DT and recipients of HSCT
were associated with a higher probability of day-30 mortality after
the development of DT.
Conclusions:Our study suggests that most cases of DT occurred
as a breakthrough infection, especially in patients who had received
MCFG. Although mortality after the development of DT was high,
it is possible that prompt initiation of treatment with azoles may
improve survival.254
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Background: Iron overload has been associated with increased
treatment-related mortality (TRM) in patients with AML/MDS un-
dergoing hematopoietic stem cell transplantation (HSCT). Defara-
sinox (D) is an orally-active iron chelator that at doses of 20 and
30 mg/kg maintain or reduce liver iron concentration in transfusion
dependent patients with MDS or hemoglobinopathies. The most
common adverse events associated with D are skin rash (26%), ab-
dominal pain (21%), and creatinine elevation (20%). These adverse
effect overlap with commonly acute side effects seen after allograft-
ing and together with the creatinine elevations make exploring the
role of D early after HSCT (ie first 90 days) difficult. Notwithstand-
ing, a significant proportion of non-relapse deaths still occur be-
tween 3 and 12 months post HSCT. Since high ferritin (F) levels
pre HSCT have been associated with increases in NRM rates post
HSCT we hypothesized that this relationship would persist even
in patients surviving more than 3 months post SCT, which would
suggest a potential role for iron chelation in patients surviving at least
3 months post HSCT.
